The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

The researchers conducted a retrospective analysis of costs associated with hospitalization of CLL patients with serious infections.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.

Justin C. Frankel, P.C., represented a client with Chronic Lymphocytic Leukemia whose long-term disability benefits ...

Explore the evolving approach to cancer treatment, emphasizing personalized care and active surveillance over aggressive ...

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in ...

Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in ...

Retrospective ONCare Alliance Network data showed lower odds of new or worsened hypertension with acalabrutinib versus ibrutinib (OR 0.27; 95% CI, 0.074–0.98). Despite older age and higher baseline ...

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta (axicabtagene ciloleucel), removing previous limitations of use for adults with relapsed ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged ...